Physician profile
Christopher Ellstrom
NPI 1578853750
$3,185.09
in general payments reported to CMS, 2019-2025
28 companies · $221 in 2025
The $221 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $169 · 2021: $669 · 2022: $1,049 · 2023: $577 · 2024: $257 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,056.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,055.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tela Bio, INC. | $886.00 | 2021-2024 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Mentor Worldwide LLC | $482.32 | 2019-2024 | Mentor Memorygel Resterilizable Gel Sizer |
| Sientra, INC. | $299.79 | 2021-2022 | |
| Galderma Laboratories, L.P. | $183.20 | 2020-2025 | Aklief |
| Allergan, INC. | $164.63 | 2021-2022 | |
| Incyte Corporation | $142.87 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $126.95 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $108.44 | 2020-2024 | Dupixent |
| Davol INC. | $100.16 | 2022 | |
| Abbvie INC. | $100.00 | 2025 | |
| Biofrontera INC. | $96.04 | 2022-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Dusa Pharmaceuticals, INC. | $64.45 | 2019 | |
| Leo Pharma INC. | $56.26 | 2025 | Adbry |
| Bard Peripheral Vascular, INC. | $41.97 | 2022 | |
| Vyne Pharmaceuticals INC. | $38.66 | 2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $36.40 | 2021-2024 | Olumiant, Taltz |
| Apyx Medical Corporation | $28.42 | 2020 | |
| Revance Therapeutics, INC. | $26.47 | 2024 | Daxxify |
| Pacira Pharmaceuticals Incorporated | $24.35 | 2022 | |
| Merz North America, INC. | $24.26 | 2024 | |
| Mayne Pharma Commercial LLC | $23.51 | 2020 | |
| Almirall LLC | $21.89 | 2023 | Seysara |
| Dermira, INC. | $21.44 | 2020 | |
| Solta Medical, A Division of Bausch Health US, LLC | $20.55 | 2019 | |
| Celgene Corporation | $20.48 | 2019 | |
| Janssen Biotech, INC. | $16.31 | 2025 | Tremfya |
| Genentech USA, INC. | $14.99 | 2019 | |
| Amgen INC. | $14.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ellstrom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.